About Us

NanoMedTrix was formed in August 2012 as a spinoff derived from decades of innovative biomedical research in nanomaterial and regenerative medicine. NMTx was founded to commercialize these scientific advances to  deploy nanoparticle products to the biomedical community. Since inception, the company has received a number of grant and awards from the University of Iowa, the NIH and NSF. NanoMedTrix received numerous awards from the State of Iowa’s Economic Development and Federal (NSF and NIH) institutions.

NanoMedTrix develops novel multi-modal, targeted contrast agents Mesoporous Silica Nanoparticles for use across a range of disciplines, including carriers for targeted drug delivery and radiology in medical imaging. Contrast agents are used to enhance the visibility of structures or fluids in the body during scans, such as MRI, CT and ultrasound.